药品专利强制许可:《多哈健康宣言》之后的发展  

Compulsory Licenses to Patented Medicines-Development after Doha Health Declaration

作　　者：冯洁菡[1] 

机构地区：[1]武汉大学法学院

出　　处：《武汉大学学报（哲学社会科学版）》2008年第5期700-705,共6页Wuhan University Journal：Philosophy & Social Science

基　　金：国家社会科学基金青年项目(04CFX026)

摘　　要：《多哈健康宣言》、《总理事会决议》以及《修订TRIPS协定议定书》所建立的"第6段机制"放宽了对医药产品的专利限制,突破了TRIPS协定关于强制许可药品主要供应国内市场的规定,从而有利于发展中国家尤其是最不发达国家进口廉价专利药品以解决公共健康问题。借鉴国际和国内层面考察实施"第6段机制"的立法和实践,我国立法应立足于促进我国公共健康事业的发展。The Paragraph 6 System established by the Doha Health Declaration, the General Council Decision and the Protocol Amending the TRIPS Agreement removed the limitation to patented medical products that the use under compulsory license shall be predominantly for the supply of the domestic market. It was favorable for developing countries and the LDCs to serve their national interests in the circumstance of public health crisis. This article elaborates legislation and practices of implementing the observes the statu Paragraph 6 System from the perspective of international law and domestic s quo of legislation in China and analyzes the existing problems.

关 键 词：强制许可 第6段机制 公共健康 TRIPS协定 

分 类 号：DF9[政治法律—国际法学]